8-K Announcements
6Material company update
May 20, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
May 13, 2026·SEC
Palvella Therapeutics, Inc.(PVLA)Earnings, Financials & Key Ratios
PVLA•NASDAQ
Price updated Jun 19, 2026
AboutPalvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. Its lead product candidate is QTORIN 3.9% rapamycin anhydrous gel (QTORIN rapamycin) that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of other mTOR-driven skin diseases. The company is based in Wayne, Pennsylvania.Show more
- Revenue$0
- EBITDA-$36M-173.7%
- Net Income-$42M-139.3%
- EPS (Diluted)-3.71+52.6%
- ROE-92.1%-55.1%
PVLA Key Insights
Palvella Therapeutics, Inc. (PVLA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Shares diluted 100.0% in last year
- ✗Expensive at 45.5x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when PVLA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PVLA Price & Volume
Palvella Therapeutics, Inc. (PVLA) stock price & volume — 10-year historical chart
Loading chart...
PVLA Growth Metrics
Palvella Therapeutics, Inc. (PVLA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-161.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM58.01%
Return on Capital
10 Years-68.9%
5 Years-74.49%
3 Years-81.9%
Last Year-62.06%
PVLA Recent Earnings
Palvella Therapeutics, Inc. (PVLA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 2/12 qtrs (67%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$1.20-33.3%
$0.90
Rev
—
—
Q2 2026
Mar 31, 2026Metric
Actual
Est
EPS
$1.08-18.5%
$0.91
Rev
—
—
Q4 2025
Nov 11, 2025Metric
Actual
Est
EPS
$1.03-21.2%
$0.85
Rev
—
—
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.86-10.3%
$0.78
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $1.20vs $0.90-33.3% | — |
| Q2 2026 | Mar 31, 2026 | $1.08vs $0.91-18.5% | — |
| Q4 2025 | Nov 11, 2025 | $1.03vs $0.85-21.2% | — |
| Q3 2025 | Aug 14, 2025 | $0.86vs $0.78-10.3% | — |
Based on last 12 quarters of dataView full earnings history →
PVLA Peer Comparison
Palvella Therapeutics, Inc. (PVLA) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 ARDX | 1.48B | 6.05 | -23.27 | 22.09% | -13.58% | -38.11% | 1.27 | |
 RCKT | 365.8M | 3.35 | -1.67 | -70.79% | 0.09 | |||
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 KRYS | 10.26B | 348.06 | 50.89 | 33.94% | 53.92% | 19.25% | 0.01 |
Compare PVLA vs Peers
Palvella Therapeutics, Inc. (PVLA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PVLA Income Statement
Palvella Therapeutics, Inc. (PVLA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 29.32M | 31.42M | 25.9M | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | -17.56% | -100% | - | - | - |
Cost of Goods Sold | 0 | 2.37M | 2.78M | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | 7.54% | 10.73% | - | - | - | - |
Gross Profit | 29.32M▲ 0% | 29.05M▼ 0.9% | 23.12M▼ 20.4% | 0▼ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% |
Gross Margin % | 100% | 92.46% | 89.27% | - | - | - | - |
Gross Profit Growth % | - | - | -20.41% | -100% | - | - | - |
Operating Expenses | 61.12M | 80.88M | 66.6M | 11.87M | 14.1M | 38.6M | 45.59M |
OpEx % of Revenue | 208.43% | 257.44% | 257.11% | - | - | - | - |
Selling, General & Admin | 16.9M | 16.68M | 16.38M | 3.08M | 5.94M | 15.76M | 17.48M |
SG&A % of Revenue | 57.62% | 53.1% | 63.25% | - | - | - | - |
Research & Development | 44.22M | 64.2M | 50.21M | 8.79M | 8.15M | 22.84M | 28.1M |
R&D % of Revenue | 150.8% | 204.33% | 193.85% | - | - | - | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -33.92M▲ 0% | -51.83M▼ 52.8% | -43.47M▲ 16.1% | -11.87M▲ 72.7% | -14.1M▼ 18.8% | -38.6M▼ 173.9% | -45.59M▲ 0% |
Operating Margin % | -115.68% | -164.97% | -167.84% | - | - | - | - |
Operating Income Growth % | - | - | 16.12% | 72.7% | -18.75% | -173.87% | - |
EBITDA | -31.79M | -49.46M | -40.69M | 18.69M | -13.12M | -35.9M | -33.95M |
EBITDA Margin % | -108.43% | -157.44% | -157.11% | - | - | - | - |
EBITDA Growth % | - | - | 17.73% | 145.93% | -170.18% | -173.67% | -109.78% |
D&A (Non-Cash Add-back) | 2.13M | 2.37M | 2.78M | 0 | 0 | 0 | 10.18M |
EBIT | -37.07M | -45.74M | -33.28M | 18.69M | -13.12M | -35.9M | -43.78M |
Net Interest Income | 511K | 4K | 721K | 6.26M | -4.32M | -3.23M | -726K |
Interest Income | 511K | 4K | 721K | 6.26M | 0 | 2.59M | 1.84M |
Interest Expense | 0 | 0 | 0 | 0 | 4.32M | 5.82M | 2.56M |
Other Income/Expense | -3.15M | 6.09M | 10.2M | 30.56M | -3.34M | -3.11M | -3.71M |
Pretax Income | -37.07M▲ 0% | -45.74M▼ 23.4% | -33.28M▲ 27.2% | 18.69M▲ 156.2% | -17.43M▼ 193.3% | -41.72M▼ 139.3% | -49.3M▲ 0% |
Pretax Margin % | -126.41% | -145.58% | -128.47% | - | - | - | - |
Income Tax | 164K | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | -0.44% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -37.23M▲ 0% | -45.74M▼ 22.9% | -33.28M▲ 27.2% | 18.69M▲ 156.2% | -17.43M▼ 193.3% | -41.72M▼ 139.3% | -49.3M▲ 0% |
Net Margin % | -126.97% | -145.58% | -128.47% | - | - | - | - |
Net Income Growth % | - | - | 27.24% | 156.17% | -193.27% | -139.27% | -161.61% |
Net Income (Continuing) | -37.23M | -45.74M | -33.28M | 18.69M | -17.43M | -41.72M | -49.3M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -54.67▲ 0% | -56.69▼ 3.7% | -29.61▲ 47.8% | 14.74▲ 149.8% | -7.83▼ 153.1% | -3.71▲ 52.6% | -3.77▲ 0% |
EPS Growth % | - | - | 47.77% | 149.78% | -153.12% | 52.62% | 58.01% |
EPS (Basic) | -54.67 | -56.69 | -29.61 | 14.74 | -7.83 | -3.71 | - |
Diluted Shares Outstanding | 681.01K | 806.84K | 930.35K | 1.27M | 2.23M | 11.25M | 13.09M |
Basic Shares Outstanding | 681.01K | 806.84K | 930.35K | 1.27M | 2.23M | 11.25M | 13.09M |
Dividend Payout Ratio | - | - | - | - | - | - | - |
PVLA Balance Sheet
Palvella Therapeutics, Inc. (PVLA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 75.72M | 127.63M | 16.52M | 7.55M | 88.23M | 58.99M | 263.23M |
Cash & Short-Term Investments | 70.44M | 117.76M | 16.05M | 7.35M | 83.6M | 57.98M | 261.85M |
Cash Only | 70.44M | 117.76M | 16.05M | 7.35M | 83.6M | 57.98M | 206.39M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 55.46M |
Accounts Receivable | 1.71M | 3.31M | 0 | 0 | 2.34M | 0 | 0 |
Days Sales Outstanding | 21.24 | 38.49 | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 3.58M | 6.55M | 471K | 198K | 2.3M | 1M | 1.38M |
Total Non-Current Assets | 29.29M | 25.93M | 0 | 0 | 0 | 572K | 528K |
Property, Plant & Equipment | 25.98M | 23.03M | 0 | 0 | 0 | 572K | 528K |
Fixed Asset Turnover | 1.13x | 1.36x | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 3.31M | 2.9M | 0 | 0 | 0 | 0 | 0 |
Total Assets | 105.01M▲ 0% | 153.56M▲ 46.2% | 16.52M▼ 89.2% | 7.55M▼ 54.3% | 88.23M▲ 1069.0% | 59.56M▼ 32.5% | 263.76M▲ 0% |
Asset Turnover | 0.28x | 0.20x | 1.57x | - | - | - | 0.00x |
Asset Growth % | - | - | -89.24% | -54.32% | 1068.97% | -32.5% | 393.92% |
Total Current Liabilities | 22.14M | 50.56M | 5.78M | 2.36M | 12.04M | 11.34M | 9.12M |
Accounts Payable | 1.79M | 8.61M | 3.18M | 936K | 4.59M | 4.59M | 5.44M |
Days Payables Outstanding | - | 1.33K | 417.65 | - | - | - | - |
Short-Term Debt | 1.03M | 1.05M | 0 | 0 | 0 | 202K | 209K |
Deferred Revenue (Current) | 12.63M | 25.12M | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 3.94M | 12.21M | 921K | 344K | 6.24M | 6.55M | 3.46M |
Current Ratio | 3.42x | 2.52x | 2.86x | 3.20x | 7.33x | 5.20x | 28.88x |
Quick Ratio | 3.42x | 2.52x | 2.86x | 3.20x | 7.33x | 5.20x | 28.88x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 51.84M | 52.24M | 33.92M | 9.07M | 13.59M | 20.23M | 22.33M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 431K | 375K |
Capital Lease Obligations | 15.93M | 13.84M | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 6K | 0 | 33.92M | 9.07M | 13.59M | 19.8M | 21.96M |
Total Liabilities | 73.98M | 102.81M | 39.7M | 11.43M | 25.63M | 31.58M | 31.45M |
Total Debt | 16.96M | 14.89M | 0 | 0 | 0 | 633K | 584K |
Net Debt | -53.47M | -102.87M | -16.05M | -7.35M | -83.6M | -57.35M | -205.81M |
Debt / Equity | 0.55x | 0.29x | - | - | - | 0.02x | 0.00x |
Debt / EBITDA | - | - | - | - | - | - | -0.02x |
Net Debt / EBITDA | - | - | - | -0.39x | - | - | 6.06x |
Interest Coverage | - | - | - | - | -3.04x | -6.17x | -17.08x |
Total Equity | 31.03M▲ 0% | 50.76M▲ 63.6% | -23.17M▼ 145.7% | -3.88M▲ 83.3% | 62.61M▲ 1713.6% | 27.98M▼ 55.3% | 232.31M▲ 0% |
Equity Growth % | - | - | -145.66% | 83.26% | 1713.58% | -55.3% | 418.14% |
Book Value per Share | 45.56 | 62.91 | -24.91 | -3.06 | 28.13 | 2.49 | 17.75 |
Total Shareholders' Equity | 31.03M | 50.76M | -23.17M | -3.88M | 62.61M | 27.98M | 232.31M |
Common Stock | 56K | 72K | 0 | 0 | 11K | 12K | 14K |
Retained Earnings | -211.41M | -257.14M | -94.99M | -76.3M | -93.73M | -135.45M | -151.22M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -295K | 829K | 0 | 0 | 3K | 83K | 95K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PVLA Cash Flow Statement
Palvella Therapeutics, Inc. (PVLA) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -45.9M | -7.66M | -14.84M | -13.7M | -10.84M | -25.01M | -29.1M |
Operating CF Margin % | -156.52% | -24.38% | -57.29% | - | - | - | - |
Operating CF Growth % | - | - | -93.73% | 7.66% | 20.89% | -130.68% | -290.85% |
Net Income | -37.23M | -45.74M | -27.55M | 18.69M | -17.43M | -41.72M | -49.3M |
Depreciation & Amortization | 2.13M | 2.37M | 0 | 0 | 0 | 0 | 0 |
Stock-Based Compensation | 0 | 0 | 427K | 603K | 830K | 6.4M | 2.57M |
Deferred Taxes | 164K | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 5.42M | 5.18M | 10.66M | -29.85M | 5.96M | 6.49M | 7.6M |
Working Capital Changes | -16.38M | 30.52M | 1.62M | -3.15M | -193K | 3.82M | 4.38M |
Change in Receivables | 5.34M | -1.81M | 0 | 0 | -1.98M | 2.49M | 2.13M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | -4.35M | 7.05M | 1.98M | -2.25M | 2.24M | 1.26M | 987K |
Cash from Investing | 39.21M | -949K | 0 | 0 | 0 | 0 | -55.44M |
Capital Expenditures | -2.73M | -949K | 0 | 0 | 0 | 0 | 0 |
CapEx % of Revenue | 9.3% | 3.02% | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 10.12M | 59.13M | 9.57M | 5M | 87.09M | -660K | 215.27M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 78.43M | 0 | 0 |
Equity Issued (Net) | 1000K | 59.13M | 9.53M | 0 | 0 | 763K | 231.65M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 34K | 5M | 8.65M | -1.42M | -16.38M |
Net Change in Cash | 8.18M▲ 0% | 47.33M▲ 478.9% | -5.27M▼ 111.1% | -8.7M▼ 65.0% | 76.25M▲ 976.2% | -25.62M▼ 133.6% | 130.77M▲ 0% |
Free Cash Flow | -48.62M▲ 0% | -8.61M▲ 82.3% | -14.84M▼ 72.4% | -13.7M▲ 7.7% | -10.84M▲ 20.9% | -25.01M▼ 130.7% | -29.1M▲ 0% |
FCF Margin % | -165.82% | -27.4% | -57.29% | - | - | - | - |
FCF Growth % | - | - | -72.38% | 7.66% | 20.89% | -130.68% | -95.76% |
FCF per Share | -71.40 | -10.67 | -15.95 | -10.81 | -4.87 | -2.22 | -2.22 |
FCF Conversion (FCF/Net Income) | 1.23x | 0.17x | 0.45x | -0.73x | 0.62x | 0.60x | 0.59x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PVLA Key Ratios
Palvella Therapeutics, Inc. (PVLA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | -90.12% | -241.3% | - | -59.37% | -92.1% | -56.87% |
Return on Invested Capital (ROIC) | - | - | - | - | - | 688.3% |
Gross Margin | 92.46% | 89.27% | - | - | - | - |
Net Margin | -145.58% | -128.47% | - | - | - | - |
Debt / Equity | 0.29x | - | - | - | 0.02x | 0.00x |
Interest Coverage | - | - | - | -3.04x | -6.17x | -17.08x |
FCF Conversion | 0.17x | 0.45x | -0.73x | 0.62x | 0.60x | 0.59x |
Revenue Growth | - | -17.56% | -100% | - | - | - |
Related:PVLA Dividend History·PVLA Revenue History·PVLA Price History·PVLA P/E History·PVLA Financial Ratios·PVLA Institutional Holders
PVLA SEC Filings & Documents
Palvella Therapeutics, Inc. (PVLA) SEC filings — annual & quarterly reports (10-K, 10-Q)
PVLA Frequently Asked Questions
Palvella Therapeutics, Inc. (PVLA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Palvella Therapeutics, Inc. (PVLA) grew revenue by 0.0% over the past year. Growth has been modest.
Palvella Therapeutics, Inc. (PVLA) reported a net loss of $49.3M for fiscal year 2025.
Dividend & Returns
Palvella Therapeutics, Inc. (PVLA) has a return on equity (ROE) of -92.1%. Negative ROE indicates the company is unprofitable.
Palvella Therapeutics, Inc. (PVLA) had negative free cash flow of $29.1M in fiscal year 2025, likely due to heavy capital investments.